Enables RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Involved in cellular response to growth factor stimulus and positive regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Biomarker of middle cerebral artery infarction. Orthologous to human EGR4 (early growth response 4); INTERACTS WITH 1,2,4-trimethylbenzene; 1-naphthyl isothiocyanate; 2,2',4,4'-Tetrabromodiphenyl ether.
early growth response protein 4; early response protein NGFI-C; EGR-4; Egr4l1; nerve growth factor-induced protein C; NGFI-C; zinc-finger transcription factor NGFI-C; zinc-finger transcription factor NGFI-C (early response gene); Zinc-finger transcription factor NGFI-C (early response gene) member of the GCGGGGGCG (GSG) element-binding protein family see D4Arb6; Zinc-finger transcription factor NGFI-C (early response gene), member of the GCGGGGGCG (GSG) element-binding protein family, see D4Arb6
[XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [bisphenol A affects the expression of EGR4 mRNA]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGR4 mRNA
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3 and 4-difluorobenzamide inhibits the reaction [Morphine results in increased expression of EGR4 mRNA]
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR4 mRNA
[XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [bisphenol A affects the expression of EGR4 mRNA] and [XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [potassium bromate affects the expression of EGR4 mRNA]